{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:08:08Z","timestamp":1789470488446,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Fibroblast growth factor receptor 2 (FGFR2) fusions are identified in approximately 10\u201316% of patients with intrahepatic cholangiocarcinoma (iCCA) and represent actionable targets, with several FGFR inhibitors approved for clinical use. To evaluate the clinical utility and assay performance of an amplicon-based next-generation sequencing (NGS) approach in this setting, we assessed FGFR2 fusion detection using the Oncomine Comprehensive Assay Plus (OCA-P). A total of 75 formalin-fixed paraffin-embedded (FFPE) specimens from biliary, pancreatic, and ampullary malignancies submitted for FGFR2 fusion testing between 1 March 2023 and 30 June 2024 were retrospectively analyzed, including 40 cases of iCCA. All iCCA specimens were successfully analyzed. FGFR2 fusions were detected exclusively in iCCA, yielding a detection rate of 20%. RNA concentrations in iCCA specimens ranged from 0.02 ng\/\u00b5L to 104 ng\/\u00b5L; six cases (15%) exhibited yields below 1 ng\/\u00b5L and 10 cases (25%) ranged between 1 and 2 ng\/\u00b5L. Despite limited RNA input, OCA-P demonstrated robust performance, successfully identifying FGFR2 fusions at concentrations below 2 ng\/\u00b5L, levels typically considered suboptimal for partner-agnostic NGS approaches. These findings support the robustness and clinical utility of the OCA-P assay for reliable FGFR2 fusion detection in iCCA, particularly in specimens with limited RNA input.<\/jats:p>","DOI":"10.3390\/curroncol33090559","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:32:01Z","timestamp":1789468321000},"page":"559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR2 Fusions in Pancreatobiliary and Ampullary Cancers: High Detection Rate in FFPE Specimens of Intrahepatic Cholangiocarcinoma with Limited RNA Yields Using Amplicon-Based NGS Assay"],"prefix":"10.3390","volume":"33","author":[{"given":"Simon","family":"Guertin","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Quebec University Hospital Center, Laval University, Quebec, QC G1R 2J6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Niloofar","family":"Sina","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Program, Department of Anatomic al Pathology, University Health Network, University of Toronto, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Ken","family":"Kron","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, North York, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9702-0830","authenticated-orcid":false,"given":"Kenneth J.","family":"Craddock","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, North York, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Amy","family":"McCarty","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, North York, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"given":"David M.","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, North York, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3604-9645","authenticated-orcid":false,"given":"Weei-Yuarn","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, North York, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107064","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_2","unstructured":"WHO Classification of Tumours Editorial Board (2019). WHO Classification of Tumours: Digestive System Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alvarez, C.S., Wojt, A., Almeida, A.A., Miller, J.S., Graubard, B.I., Petrick, J.L., and McGlynn, K.A. (2025). Rising intrahepatic cholangiocarcinoma rates in the United States are driving liver cancer rates in females. Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/j.cgh.2025.12.013"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/cco.2018.07.03","article-title":"Intrahepatic cholangiocarcinoma: The AJCC\/UICC 8th edition updates","volume":"7","author":"Lee","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","article-title":"Intrahepatic cholangiocarcinoma","volume":"28","author":"Pawlik","year":"2019","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.37349\/etat.2022.00079","article-title":"Genomic alterations in cholangiocarcinoma: Clinical significance and relevance to therapy","volume":"3","author":"Carotenuto","year":"2022","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Valery, M., Vasseur, D., Fachinetti, F., Boil\u00e8ve, A., Smolenschi, C., Tarabay, A., Antoun, L., Perret, A., Fuerea, A., and Pudlarz, T. (2023). Targetable molecular alterations in the treatment of biliary tract cancers: An overview of the available treatments. Cancers, 15.","DOI":"10.3390\/cancers15184446"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/1078-0432.CCR-22-2036","article-title":"FDA approval summary: Pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xin, X., and Miao, R. (2026). FGFR2-rearranged biliary tract cancer: Biology, resistance mechanisms, and emerging therapeutic strategies. Cancers, 18.","DOI":"10.3390\/cancers18030531"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","article-title":"Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges","volume":"40","author":"Chen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14737159.2025.2518145","article-title":"Best practices in sample management and molecular profiling of cholangiocarcinoma: A practical guide","volume":"25","author":"Castet","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"De Luca, A., Esposito Abate, R., Rachiglio, A.M., Maiello, M.R., Esposito, C., Schettino, C., Izzo, F., Nasti, G., and Normanno, N. (2020). FGFR fusions in cancer: From diagnostic approaches to therapeutic intervention. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186856"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Heydt, C., W\u00f6lwer, C.B., Velazquez Camacho, O., Wagener-Ryczek, S., Pappesch, R., Siemanowski, J., Rehker, J., Haller, F., Agaimy, A., and Worm, K. (2021). Detection of gene fusions using targeted next-generation sequencing: A comparative evaluation. BMC Med. Genom., 14.","DOI":"10.1186\/s12920-021-00909-y"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cjp2.308","article-title":"First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma","volume":"9","author":"Neumann","year":"2023","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00428-025-04067-9","article-title":"FGFR2 fusion\/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA\/RNA-based NGS and FISH","volume":"487","author":"Zhang","year":"2025","journal-title":"Virchows Arch."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2307\/2982890","article-title":"Fisher\u2019s exact test","volume":"155","author":"Upton","year":"1992","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Olkhov-Mitsel, E., Chan, D., Craddock, K.J., Lin, A., Luk, G., Goswami, R.S., Wang, H., Plotkin, A., Nofech-Mozes, S., and Hwang, D.M. (2024). Analytical validation and performance evaluation of amplicon-based next-generation sequencing assays for detecting ERBB2 and other gene amplifications in solid tumors. Cancers, 16.","DOI":"10.3390\/cancers16233927"},{"key":"ref_22","first-page":"1355","article-title":"Molecular detection of FGFR2 rearrangements in resected intrahepatic cholangiocarcinomas: FISH could be an ideal method in patients with histological small duct subtype","volume":"11","author":"Zou","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:57:56Z","timestamp":1789469876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090559"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090559","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}